COMP <GO>
ACAD vs ABBV // RETURN ON INVESTED CAPITAL (ROIC)
ACADIA Pharmaceuticals Inc. (NASDAQ) VS. AbbVie Inc. (NYSE) • 15-METRIC TALLY: ACAD 6
— ABBV 6
▲ RETURN ON INVESTED CAPITAL (ROIC) LEADER: ABBV
LAST: $20.76 (+2.17%) • MKT CAP: $3.58B
roic
7.90%
LAST: $290.79 (+1.68%) • MKT CAP: $513.86B
roic
29.00%
15-METRIC INSTITUTIONAL SIDE-BY-SIDE SCORECARD (ACAD VS. ABBV)
EMERALD CELL = QUANTITATIVE EDGE
| INSTITUTIONAL METRIC | ACAD | ABBV | SPREAD (A - B) | ADVANTAGE | DEDICATED URL |
|---|---|---|---|---|---|
| Gross Profit Margin | 91.70% | 70.20% | +21.50 | ACAD | /gross-margins <GO> |
| Return on Invested Capital (ROIC) ACTIVE | 7.90% | 29.00% | -21.10 | ABBV | /roic <GO> |
| EV/EBITDA & P/E Valuation | 31.2x | 33.3x | -2.10 | ACAD | /valuation <GO> |
| Free Cash Flow Yield | 2.94% | 3.47% | -0.53 | ABBV | /fcf-yield <GO> |
| Operating Margin | 9.80% | 24.60% | -14.80 | ABBV | /operating-margins <GO> |
| Net Profit Margin | 36.50% | 6.90% | +29.60 | ACAD | /net-margins <GO> |
| Revenue Growth (YoY) | 11.90% | 8.60% | +3.30 | ACAD | /revenue-growth <GO> |
| Dividend Yield & FCF Payout Safety | 0.00% | 2.27% | -2.27 | ABBV | /dividend-safety <GO> |
| Altman Z-Score & Debt/Equity | 6.26 | 5.33 | +0.93 | ACAD | /balance-sheet <GO> |
| Piotroski F-Score Quality | 7/9 | 7/9 | 0.00 | TIE | /piotroski-score <GO> |
| Options Implied Move & Put/Call Skew | — | — | — | TIE | /options-implied-move <GO> |
| RSI-14 & 200D SMA Momentum | 45.5 | 65.1 | -19.58 | ABBV | /rsi-technicals <GO> |
| 10Y Yield & FRED Macro Beta | — | 1.15 | — | TIE | /macro-sensitivity <GO> |
| Forward P/E Multiple | 8.5x | 113.1x | -104.60 | ACAD | /forward-pe <GO> |
| Enterprise Scale & Market Cap | $3.58B | $513.86B | -$510.28B | ABBV | /market-cap <GO> |
5-YEAR HISTORICAL XBRL REVENUE & MARGIN TRAJECTORY SEC FORM 10-K FY
| FISCAL YEAR | ACAD REV | ABBV REV | ACAD GROSS % | ABBV GROSS % | ACAD FCF | ABBV FCF |
|---|---|---|---|---|---|---|
| FY 2025 | $1.07B | $61.16B | 91.7% | 70.2% | $105.1M | $17.82B |
| FY 2024 | $957.8M | $56.33B | 91.5% | 70.0% | $157.2M | $17.83B |
| FY 2023 | $726.4M | $54.32B | — | — | $16.7M | $20.39B |
FRED MACRO REGIME CORRELATION COMPARISON PEARSON r
ACAD // BETA —
ABBV // BETA 1.15